利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.034 秒)

    Fat emulsion containing steroid
    5.
    发明授权
    Fat emulsion containing steroid 失效
    包含类固醇的脂肪乳液

    公开(公告)号：US4340594A

    公开(公告)日：1982-07-20

    申请号：US260607

    申请日：1981-05-06

    申请人： Yutaka Mizushima ,  Kazumasa Yokoyama ,  Kiichiro Nabeta ,  Noboru Yamada ,  Tadakazu Suyama

    发明人： Yutaka Mizushima ,  Kazumasa Yokoyama ,  Kiichiro Nabeta ,  Noboru Yamada ,  Tadakazu Suyama

    IPC分类号： A61K9/10 ,  A61K9/107 ,  A61K9/14 ,  A61K31/57 ,  A61K31/704 ,  A61P29/00 ,  A61K31/56

    CPC分类号： A61K9/1075 ,  A61K31/57

    摘要： A fat emulsion containing a steroid having an anti-inflammatory activity, comprising an effective quantity of a steroid having an anti-inflammatory activity, 5 to 50% (W/V) of soybean oil, a phospholipid in a weight ratio of 1-50 to 100 of said soybean oil, and a proper quantity of water. This fat emulsion exhibits a long-lasting activity in the region of inflammation and is especially useful in the therapeutic or prophylactic treatment of rheumatism, immunological hemolytic anemia, idiopathic thrombocytopenic purpura, and Paget disease, or in conjunction with kidney transplantation.

    摘要翻译： 含有具有抗炎活性的类固醇的脂肪乳剂，其包含有效量的具有抗炎活性的类固醇，大豆油为5〜50％（W / V），重量比为1〜50的磷脂 至100份所述大豆油，并加入适量的水。 这种脂肪乳剂在炎症区域表现出持久的活性，特别可用于治疗或预防性治疗风湿病，免疫性溶血性贫血，特发性血小板减少性紫癜和佩吉特病，或与肾移植有关。

    THERAPEUTIC COMPOSITION FOR INTERSTITUAL PNEUMONIA
    7.
    发明申请
    THERAPEUTIC COMPOSITION FOR INTERSTITUAL PNEUMONIA 审中-公开
    间接肺炎的治疗组合物

    公开(公告)号：US20100143321A1

    公开(公告)日：2010-06-10

    申请号：US12519437

    申请日：2007-12-19

    申请人： Kouji Shirai ,  Tatsuo Kawashima ,  Toshihisa Kuroda ,  Yutaka Mizushima ,  Ayako Mizushima ,  Masahiro Murakami ,  Tomoharu Fukuzaki

    发明人： Kouji Shirai ,  Tatsuo Kawashima ,  Toshihisa Kuroda ,  Yutaka Mizushima ,  Ayako Mizushima ,  Masahiro Murakami ,  Tomoharu Fukuzaki

    IPC分类号： A61K38/44 ,  A61P11/00

    CPC分类号： A61K31/573 ,  A61K9/0019 ,  A61K38/00 ,  A61K47/26 ,  A61K47/544 ,  C12N9/0089

    摘要： A therapeutic agent for interstitial pneumonia is provided which effectively exploits the effect of superoxide dismutase (SOD). The therapeutic composition for interstitial pneumonia contains 10 to 100 mg of lecithinized superoxide dismutase represented by the following general formula (I): SOD′(Q-B)m   (I) (wherein SOD′ is a residue of superoxide dismutase; Q is a chemical crosslink; B is a residue of lysolecithin having the hydrogen atom of the hydroxyl group at position 2 of its glycerol moiety removed; and m is the average number of lysolecithin molecules bound to one molecule of the superoxide dismutase and is an integer of 1 or greater) and further contains sucrose to give it a stable form suitable for intravenous administration.

    摘要翻译： 提供间质性肺炎治疗剂，有效利用超氧化物歧化酶（SOD）的作用。 间质性肺炎的治疗组合物含有10-100mg由以下通式（I）表示的卵磷脂化超氧化物歧化酶：SOD'（QB）m（I）（其中SOD'是超氧化物歧化酶的残基; Q是化学交联 ; B是除去其甘油部分的位置2处的羟基的氢原子的溶血卵磷脂的残基; m是与1分子超氧化物歧化酶结合的溶血卵磷脂分子的平均数，为1以上的整数） 并且还含有蔗糖以使其具有适于静脉内施用的稳定形式。

    SUSTAINED-RELEASE NANOPARTICLE CONTAINING LOW-MOLECULAR-WEIGHT DRUG WITH NEGATIVELY CHARGED GROUP
    8.
    发明申请
    SUSTAINED-RELEASE NANOPARTICLE CONTAINING LOW-MOLECULAR-WEIGHT DRUG WITH NEGATIVELY CHARGED GROUP 审中-公开
    含有低分子量药物的含有低分子量药物的持续释放纳米颗粒

    公开(公告)号：US20100129456A1

    公开(公告)日：2010-05-27

    申请号：US12597969

    申请日：2008-04-11

    申请人： Tsutomu Ishihara ,  Yutaka Mizushima ,  Ayako Mizushima ,  Toru Mizushima

    发明人： Tsutomu Ishihara ,  Yutaka Mizushima ,  Ayako Mizushima ,  Toru Mizushima

    IPC分类号： A61K9/14

    CPC分类号： A61K9/5153 ,  A61K9/19 ,  A61K9/5192 ,  A61K31/00 ,  A61K45/06

    摘要： A nanoparticle containing a low-molecular-weight drug having a negatively charged group is provided that is effectively targeted to an affected site, is capable of sufficiently sustained release of the drug, and has a reduced tendency to accumulate in the liver to cause reduced side effects. The nanoparticle containing a low-molecular-weight drug having a negatively charged group is obtained by hydrophobicizing the low-molecular-weight drug having a negatively charged group with a metal ion, and reacting the hydrophobicized drug with poly L-lactic acid or poly(L-lactic acid/glycolic acid) copolymer and poly DL- or L-lactic acid-polyethylene glycol block copolymer or poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer.

    摘要翻译： 提供了含有具有带负电荷的基团的低分子量药物的纳米粒子，其有效靶向受影响部位，能够充分持续释放药物，并且具有减少的积聚在肝脏中的趋势，导致减少的侧面 效果。 含有带负电荷基团的低分子量药物的纳米粒子是通过用金属离子疏水化具有带负电荷的基团的低分子量药物，并使疏水化药物与聚-L-乳酸或聚（ L-乳酸/乙醇酸）共聚物和聚DL-或L-乳酸 - 聚乙二醇嵌段共聚物或聚（DL-或L-乳酸/乙醇酸） - 聚乙二醇嵌段共聚物。

    Zinc-containing sustained-release composition, its preparation, and method for producing the same
    9.
    发明授权
    Zinc-containing sustained-release composition, its preparation, and method for producing the same 失效
    含锌缓释组合物及其制备方法及其制备方法

    公开(公告)号：US07642230B2

    公开(公告)日：2010-01-05

    申请号：US10555191

    申请日：2004-04-01

    申请人： Michio Kimura ,  Tomoko Eto ,  Yutaka Mizushima

    发明人： Michio Kimura ,  Tomoko Eto ,  Yutaka Mizushima

    IPC分类号： A61K38/02 ,  A61K33/30 ,  A61K33/42

    CPC分类号： C07K16/241 ,  A61K9/0019 ,  A61K9/10 ,  A61K33/30 ,  A61K38/193 ,  A61K38/212 ,  A61K38/27 ,  A61K45/06 ,  A61K47/02 ,  A61K2300/00

    摘要： With a simple and high-yield production method, a zinc-containing sustained-release composition capable of stabilizing a physiologically active protein or peptide, typically G-CSF by precipitation and retaining drug efficacy for several days in a living body owing to its sustained releasability is provided. Concretely, a zinc-containing sustained-release composition produced by forming a precipitate by mixing a physiologically active protein or peptide, a water-soluble zinc salt, a water-soluble carbonate and/or a water soluble phosphate aqueous solution. The zinc-containing sustained-release composition may be administered as a zinc-containing sustained preparation by adding a pharmaceutically acceptable additive as is necessary.

    摘要翻译： 通过简单且高产量的生产方法，能够通过沉淀稳定生理活性蛋白质或肽，通常为G-CSF的锌含量缓释组合物，由于其具有持续的释放性，在活体中保持药物疗效几天 被提供。 具体地说，通过混合生理活性蛋白质或肽，水溶性锌盐，水溶性碳酸盐和/或水溶性磷酸盐水溶液形成沉淀物而制备的含锌缓释组合物。 含锌持续释放组合物可以通过根据需要添加药学上可接受的添加剂作为含锌缓释制剂施用。

    Method for Screening for Compounds Safe for Gastric Mucosa
    10.
    发明申请
    Method for Screening for Compounds Safe for Gastric Mucosa 审中-公开
    筛选胃粘膜安全的化合物的方法

    公开(公告)号：US20080113014A1

    公开(公告)日：2008-05-15

    申请号：US10597483

    申请日：2004-12-15

    申请人： Toru Mizushima ,  Yutaka Mizushima

    发明人： Toru Mizushima ,  Yutaka Mizushima

    IPC分类号： A61K9/127 ,  G01N33/92 ,  A61K31/192 ,  A61K31/60 ,  A61K31/56

    CPC分类号： G01N33/5076 ,  G01N33/5008 ,  G01N33/5014 ,  G01N33/5432 ,  G01N33/582 ,  G01N33/586 ,  G01N2500/00

    摘要： A method for screening for compounds or salts thereof, in particular nonsteroidal anti-inflammatory compounds or salts thereof, that are safe for gastric mucosa and cause little gastrointestinal side effects. The method uses a particular liposome to serve as a cell membrane model. The liposome encapsulates a fluorescent dye, in particular, calcein and is formed of phospholipids, such as phosphatidylcholine, phosphatidylglycerol, phosphatidylserine, and phosphatidylinositol. A test compound is allowed to react with the liposome and the leakage of the fluorescent dye from the liposome is evaluated. As a result, compounds safe for gastric mucosa, in particular, anti-inflammatory compounds can be screened.

    摘要翻译： 用于筛选其对胃粘膜安全并且引起很少胃肠道副作用的化合物或其盐，特别是非甾体抗炎化合物或其盐的方法。 该方法使用特定的脂质体作为细胞膜模型。 脂质体封装荧光染料，特别是钙黄绿素，并由磷脂形成，例如磷脂酰胆碱，磷脂酰甘油，磷脂酰丝氨酸和磷脂酰肌醇。 使测试化合物与脂质体反应，并评估荧光染料从脂质体的泄漏。 因此，可以筛选对胃粘膜，特别是抗炎化合物安全的化合物。